Trump delays tariff hike suggesting progress on US-China trade talks

Yesterday, an extended week of talks between the US and China on trade issues ended, that were commented by US President Trump as “productive” and also on the Chinese side, the press reported substantial progress.


  • On Sunday, US President Trump announced that he would delay to an unspecified date the tariff increase on imports from China which were scheduled to start on March 1.
  • Trump acknowledged “productive” trade talks and also the Chinese press reported substantial progress. Trump and Xi are reportedly planning to meet for a summit later in March at Trump’s Mar-a-Lago resort.
  • Details about the progress were not given. News from last week point to steps forward to narrow the bilateral trade deficit as well as on ensuring intellectual property rights and tackling alleged forced technology transfer.
  • The postponement of the deadline increases the chances of a deal and reduces the risk of a further escalation of the trade conflict, an important source of current global uncertainty. However, given the complexity of the matter, a positive negotiation result is not a done deal yet and existing tariffs could well be maintained for some time.
  • The Chinese stock market rallied on the news and the Chinese currency appreciated versus the US-dollar.

Download the full publication below



After the rescue. As we enter the 20H2, Covid-19 is still lurking around, and influ-encing our social and economic behaviours. The number of new daily cases globally is at a new high.
Market Compass July 2020
Edited by the Macro & Market Research Team. The team of 13 analysts based in Paris, Cologne, Trieste, Milan and Prague runs qualitative and quantitative analysis on macroeconomic and financial issues.
The team translates macro and quant views into investment ideas that feed into the investment process.
According to the World Health Organization, there are 18 candidate vaccines in clinical evaluation globally. The most advanced one, which is already in phase 3, is being developed by the University of Oxford and AstraZeneca.